Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region

Ran Xu Zhu, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Ran Xu Zhu, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen

Abstract

Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the past two decades, the incidence of HCC has remained stable in countries in the region except for Singapore and Hong Kong, where the incidence for both sexes is currently decreasing. Chronic hepatitis C infection (CHC) is an important cause of HCC in Japan, representing 70% of HCCs. Over the past several decades, the prevalence of CHC has been increasing in many Asia-Pacific countries, including Australia, New Zealand, and India. Despite advancements in treatment, HCC is still an important health problem because of the associated substantial mortality. An effective surveillance program could offer early diagnosis and hence better treatment options. Antiviral treatment for both CHB and CHC is effective in reducing the incidence of HCC.

Keywords: Carcinoma, hepatocellular; Incidence; Liver neoplasms; Mortality; Prevalence.

Figures

Fig. 1
Fig. 1
The proportions of hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related hepatocellular carcinoma in different Asia-Pacific regions. The data source for each country was as follows: China, Hong Kong, India, Japan, Singapore, Korea, and Taiwan.
Fig. 2
Fig. 2
The incidence rates of hepatocellular carcinoma (HCC) in both sexes among different age groups in Hong Kong (data from the report of the Hong Kong Cancer Registry, 2012). Age-specific incidence rates for liver cancer in 2012.
Fig. 3
Fig. 3
The relative incidences of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in different Asia-Pacific regions.,
Fig. 4
Fig. 4
Summary of the age-standardized incidence rates of hepatocellular carcinoma (HCC) for men and women in different countries of the Asia-Pacific region between 2000 and 2005. Time periods of the incidences in each country: China, 2002 to 2005; Hong Kong, 2005; India, 2001 to 2004; Japan, 2000; Korea, 2003; New Zealand, 2004; Singapore, 2002 to 2005; and Taiwan, 2002.

References

    1. Boyle P, Levin B. World cancer report 2008. Lyon: IARC Press; 2008.
    1. Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998–2003. Prev Chronic Dis. 2008;5:A74.
    1. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010;58:273–277. doi: 10.1016/j.patbio.2010.01.005.
    1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–2094. doi: 10.1016/S0140-6736(03)15108-2.
    1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42( Suppl 3):S206–S214. doi: 10.1016/S1590-8658(10)60507-5.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74.
    1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–458. doi: 10.1038/nrgastro.2010.100.
    1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–4308. doi: 10.3748/wjg.14.4300.
    1. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13(9 Pt 2):S169–S171. doi: 10.1016/S1051-0443(07)61783-7.
    1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576. doi: 10.1053/j.gastro.2007.04.061.
    1. Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111–1118. doi: 10.1016/S1470-2045(09)70241-4.
    1. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13–20. doi: 10.1111/j.1749-6632.2002.tb04090.x.
    1. Blumberg BS, Larouzé B, London WT, et al. The relation of infection with the hepatitis B agent to primary hepatic carcinoma. Am J Pathol. 1975;81:669–682.
    1. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–5107. doi: 10.1038/sj.onc.1206557.
    1. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:3–23. doi: 10.1016/j.bpg.2004.10.004.
    1. Nguyen VT, Razali K, Amin J, Law MG, Dore GJ. Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. J Gastroenterol Hepatol. 2008;23:922–929. doi: 10.1111/j.1440-1746.2007.05065.x.
    1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. doi: 10.1001/jama.295.1.65.
    1. Chen CJ, Yang HI, Iloeje UH REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–S84. doi: 10.1002/hep.22884.
    1. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138:1747–1754. doi: 10.1053/j.gastro.2010.01.042.
    1. Han YF, Zhao J, Ma LY, et al. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258–4270. doi: 10.3748/wjg.v17.i38.4258.
    1. Tseng TC, Liu CJ, Chen CL, et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis. 2013;208:584–593. doi: 10.1093/infdis/jit209.
    1. Geier A, Gartung C, Dietrich CG. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:1721–1722. doi: 10.1056/NEJM200211213472119.
    1. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20:5427–5434. doi: 10.3748/wjg.v20.i18.5427.
    1. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494–1498. doi: 10.1136/gut.2003.033324.
    1. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149.e3. doi: 10.1053/j.gastro.2012.02.007.
    1. Lu SN, Lin TM, Chen CJ, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer. 1988;62:2051–2055. doi: 10.1002/1097-0142(19881101)62:9<2051::AID-CNCR2820620930>;2-1.
    1. Fasani P, Sangiovanni A, De Fazio C, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology. 1999;29:1704–1707. doi: 10.1002/hep.510290604.
    1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–3044. doi: 10.1002/ijc.21731.
    1. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008;14:1652–1656. doi: 10.3748/wjg.14.1652.
    1. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–331. doi: 10.1093/aje/155.4.323.
    1. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675–680. doi: 10.1056/NEJM199109053251002.
    1. Zhang YJ, Chen Y, Ahsan H, et al. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett. 2005;221:135–143. doi: 10.1016/j.canlet.2004.08.028.
    1. Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology. 1998;27:383–391. doi: 10.1002/hep.510270211.
    1. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28:109–122. doi: 10.1002/dmrr.1291.
    1. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–1648. doi: 10.1002/ijc.26165.
    1. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533–539. doi: 10.1136/gut.2004.052167.
    1. Ohishi W, Fujiwara S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2008;17:846–854. doi: 10.1158/1055-9965.EPI-07-2806.
    1. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978–1997: increasing incidence and mortality. Med J Aust. 2000;173:403–405.
    1. Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20:873–881. doi: 10.1111/j.1440-1746.2005.03844.x.
    1. Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol. 2011;26:1757–1764. doi: 10.1111/j.1440-1746.2011.06785.x.
    1. O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health. 2004;28:212–216. doi: 10.1111/j.1467-842X.2004.tb00477.x.
    1. Amin J, O’Connell D, Bartlett M, et al. Liver cancer and hepatitis B and C in New South Wales, 1990–2002: a linkage study. Aust N Z J Public Health. 2007;31:475–482. doi: 10.1111/j.1753-6405.2007.00121.x.
    1. Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21:401–416. doi: 10.2188/jea.JE20100190.
    1. Fan JH, Wang JB, Jiang Y, et al. Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev. 2013;14:7251–7256. doi: 10.7314/APJCP.2013.14.12.7251.
    1. Zhou X, Tang Z, Yu Y. Changing prognosis of primary liver cancer: some aspects to improve long-term survival. Zhonghua Zhong Liu Za Zhi. 1996;18:211–213.
    1. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2:61.
    1. Lin J. A study on aetiological factors of primary hepato-carcinoma in Tianjin China. Zhonghua Liu Xing Bing Xue Za Zhi. 1991;12:346–349.
    1. Chen JG, Zhu J, Parkin DM, et al. Trends in the incidence of cancer in Qidong, China, 1978–2002. Int J Cancer. 2006;119:1447–1454. doi: 10.1002/ijc.21952.
    1. Hong Kong Cancer Registry. Overview of Hong Kong cancer statistics [Internet] Hong Kong: Hospital Authority; 2015. [cited 2015 Apr 15]. Available from .
    1. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology. 2000;31:330–335. doi: 10.1002/hep.510310211.
    1. Yeole BB. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev. 2008;9:97–100.
    1. Kumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22:1104–1111. doi: 10.1111/j.1440-1746.2007.04908.x.
    1. Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008;148:820–826. doi: 10.7326/0003-4819-148-11-200806030-00004.
    1. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44( Suppl 19):102–107. doi: 10.1007/s00535-008-2251-0.
    1. Park JW. Hepatocellular carcinoma in Korea: introduction and overview. Korean J Gastroenterol. 2005;45:217–226.
    1. Medical Council of New Zealand. Best health outcomes for Pacific peoples: practice implications. Wellington: Medical Council of New Zealand; 2010.
    1. Meredith I, Sarfati D, Ikeda T, Blakely T. Cancer in Pacific people in New Zealand. Cancer Causes Control. 2012;23:1173–1184. doi: 10.1007/s10552-012-9986-x.
    1. Fernandes ML, Chan YH, Lim SG. Trends in the incidence of hepatocellular carcinoma in Singapore 1968–2002. Hepatology. 2007;46(4 Suppl 1):418A.
    1. Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer. 2006;119:1946–1952. doi: 10.1002/ijc.22045.
    1. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–1859. doi: 10.1056/NEJM199706263362602.
    1. Yuen MF, Hou JL, Chutaputti A Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346–353. doi: 10.1111/j.1440-1746.2009.05784.x.
    1. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55( Suppl 1):S3–S9. doi: 10.1093/cid/cis393.
    1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. doi: 10.1016/S0140-6736(15)61412-X.
    1. Lai CL, Lam KC, Wong KP, Wu PC, Todd D. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer. 1981;47:2746–2755. doi: 10.1002/1097-0142(19810601)47:11<2746::AID-CNCR2820471134>;2-K.
    1. Lai CL, Gregory PB, Wu PC, Lok AS, Wong KP, Ng MM. Hepatocellular carcinoma in Chinese males and females: possible causes for the male predominance. Cancer. 1987;60:1107–1110. doi: 10.1002/1097-0142(19870901)60:5<1107::AID-CNCR2820600531>;2-O.
    1. Shiu W, Dewar G, Leung N, et al. Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases. Oncology. 1990;47:241–245. doi: 10.1159/000226823.
    1. Leung NW, Tam JS, Lai JY, et al. Does hepatitis C virus infection contribute to hepatocellular carcinoma in Hong Kong? Cancer. 1992;70:40–44. doi: 10.1002/1097-0142(19920701)70:1<40::AID-CNCR2820700107>;2-P.
    1. Cheung TK, Lai CL, Wong BC, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573–583. doi: 10.1111/j.1365-2036.2006.03029.x.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj